497833-27-9

Givinostat (ITF-2357) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat can be used for Duchenne muscular dystrophy (DMD) research[1].

ChEBI: N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester is a carbamate ester.

hHDAC3: 157 nM (IC₅₀); HD1-B: 7.5 nM (IC₅₀); HD1-A: 16 nM (IC₅₀); HD2: 10 nM (IC₅₀); hHDAC1: 198 nM (IC₅₀); hHDAC11: 292 nM (IC₅₀); hHDAC6: 315 nM (IC₅₀); hHDAC2: 325 nM (IC₅₀); hHDAC10: 340 nM (IC₅₀); hHDAC7: 524 nM (IC₅₀); hHDAC5: 532 nM (IC₅₀); hHDAC9: 541 nM (IC₅₀); hHDAC8: 854 nM (IC₅₀); hHDAC4: 1059 nM (IC₅₀)

Store at -20°C

[1] Li S, et al. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo. J Biol Chem. 2015 Jan 23;290(4):2368-78. DOI:10.1074/jbc.M114.618454
[2] Leoni F, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005 Jan-Dec;11(1-12):1-15. DOI:10.2119/2006-00005.Dinarello
[3] Wang YG, et al. Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation. World J Gastroenterol. 2015 Jul 21;21(27):8326-39. DOI:10.3748/wjg.v21.i27.8326